{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:03:42Z","timestamp":1793239422805,"version":"4.5.0"},"reference-count":104,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32HL110837"],"award-info":[{"award-number":["T32HL110837"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["79260132"],"award-info":[{"award-number":["79260132"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.pcad.2024.12.010","type":"journal-article","created":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T16:55:30Z","timestamp":1735577730000},"page":"102-112","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["Anti-consumption agents: Tirzepatide and semaglutide for treating obesity-related diseases and addictions, and improving life expectancy"],"prefix":"10.1016","volume":"89","author":[{"given":"James H.","family":"O'Keefe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Grant","family":"Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan L.","family":"O'Keefe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pcad.2024.12.010_bb0005","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/oby.23897","article-title":"Ultraprocessed, hyper-palatable, and high energy density foods: prevalence and distinction across 30 years in the United States","volume":"32","author":"Sutton","year":"2024","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.pcad.2024.12.010_bb0010","doi-asserted-by":"crossref","first-page":"20220214","DOI":"10.1098\/rstb.2022.0214","article-title":"From dearth to excess: the rise of obesity in an ultra-processed food system","volume":"378","author":"Hall","year":"2023","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"10.1016\/j.pcad.2024.12.010_bb0015","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.pcad.2023.04.004","article-title":"Cardiology and lifestyle medicine","volume":"77","author":"Rozanski","year":"2023","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.pcad.2024.12.010_bb0020","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1186\/s12888-024-05889-8","article-title":"Association between junk food consumption and mental health problems in adults: a systematic review and meta-analysis","volume":"24","author":"Ejtahed","year":"2024","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.pcad.2024.12.010_bb0025","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.mehy.2008.11.035","article-title":"Refined food addiction: a classic substance use disorder","volume":"72","author":"Ifland","year":"2009","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.pcad.2024.12.010_bb0030","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13146","article-title":"Ultraprocessed food and chronic noncommunicable diseases: a systematic review and meta-analysis of 43 observational studies","volume":"22","author":"Lane","year":"2021","journal-title":"Obes Rev"},{"key":"10.1016\/j.pcad.2024.12.010_bb0035","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41398-023-02447-w","article-title":"Obesity as pleiotropic risk state for metabolic and mental health throughout life","volume":"13","author":"Leutner","year":"2023","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.pcad.2024.12.010_bb0040","doi-asserted-by":"crossref","DOI":"10.3390\/nu13082636","article-title":"Sugar- and artificially sweetened beverages consumption linked to type 2 diabetes, cardiovascular diseases, and all-cause mortality: a systematic review and dose-response Meta-analysis of prospective cohort studies","volume":"13","author":"Meng","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.pcad.2024.12.010_bb0045","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1017\/S0007114520002688","article-title":"Consumption of ultra-processed foods and health status: a systematic review and meta-analysis","volume":"125","author":"Pagliai","year":"2021","journal-title":"Br J Nutr"},{"key":"10.1016\/j.pcad.2024.12.010_bb0050","doi-asserted-by":"crossref","DOI":"10.3390\/nu14010174","article-title":"Ultra-processed food consumption and adult mortality risk: a systematic review and dose-response Meta-analysis of 207,291 participants","volume":"14","author":"Suksatan","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.pcad.2024.12.010_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pcad.2023.05.001","article-title":"Adipo-cardiology: the next frontier in cardiovascular disease","volume":"78","author":"Neeland","year":"2023","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.pcad.2024.12.010_bb0060","series-title":"Services UDoHH","article-title":"Adult Obesity Prevalence Maps","year":"2023"},{"key":"10.1016\/j.pcad.2024.12.010_bb0065","series-title":"Vol NCHS Date Brief No. 508, September 2024","article-title":"Obesity and severe obesity prevalence in adults: United States, August 2021\u2013August 2023","author":"Emmerich","year":"2024"},{"key":"10.1016\/j.pcad.2024.12.010_bb0070","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ajcnut.2022.10.012","article-title":"Incidence of obesity across adulthood in the United States, 2001-2017-a national prospective analysis","volume":"117","author":"Nielsen","year":"2023","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.pcad.2024.12.010_bb0075","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.amepre.2022.01.012","article-title":"Obesity prevalence among U.S. adults during the COVID-19 pandemic","volume":"63","author":"Restrepo","year":"2022","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.pcad.2024.12.010_bb0080","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.pcad.2024.01.003","article-title":"Update on obesity, the obesity paradox, and obesity management in heart failure","volume":"82","author":"Alebna","year":"2024","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.pcad.2024.12.010_bb0085","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.pcad.2023.04.010","article-title":"Obesity and atrial fibrillation: prevalence, pathogenesis, and prognosis","volume":"78","author":"Middeldorp","year":"2023","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.pcad.2024.12.010_bb0090","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.pcad.2022.11.013","article-title":"Updates on obesity and the obesity paradox in cardiovascular diseases","volume":"78","author":"Tutor","year":"2023","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.pcad.2024.12.010_bb0095","author":"Dattani"},{"key":"10.1016\/j.pcad.2024.12.010_bb0100","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.7067","article-title":"Changes in life expectancy between 2019 and 2020 in the US and 21 peer countries","volume":"5","author":"Woolf","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.pcad.2024.12.010_bb0105","first-page":"1","article-title":"United States life tables, 2021","volume":"72","author":"Arias","year":"2023","journal-title":"Natl Vital Stat Rep"},{"key":"10.1016\/j.pcad.2024.12.010_bb0110","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/s41562-022-01450-3","article-title":"Life expectancy changes since COVID-19","volume":"6","author":"Scholey","year":"2022","journal-title":"Nat Hum Behav"},{"key":"10.1016\/j.pcad.2024.12.010_bb0115","author":"Rakshit"},{"key":"10.1016\/j.pcad.2024.12.010_bb0120","unstructured":"Drug Use by Country https:\/\/worldpopulationreview.com\/country-rankings\/drug-use-by-country. Lancaster, PA: World Population Review; 2024."},{"key":"10.1016\/j.pcad.2024.12.010_bb0125","series-title":"Deaths of Despair and the Future of Capitalism","author":"Case","year":"2021"},{"key":"10.1016\/j.pcad.2024.12.010_bb0130","series-title":"Opioid Use Disorder Death Rate - https:\/\/ourworldindata.org\/grapher\/death-rate-from-opioid-use. Our World in Data","author":"IHME GBoD","year":"2024"},{"key":"10.1016\/j.pcad.2024.12.010_bb0135","article-title":"New clinical and public health challenges: increasing trends in United States alcohol related mortality","author":"Matarazzo","year":"2024","journal-title":"Am J Med"},{"key":"10.1016\/j.pcad.2024.12.010_bb0140","doi-asserted-by":"crossref","first-page":"154","DOI":"10.15585\/mmwr.mm7308a1","article-title":"Deaths from excessive alcohol use - United States, 2016-2021","volume":"73","author":"Esser","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.pcad.2024.12.010_bb0145","series-title":"Statista. September 27","article-title":"Online shopping behavior in the United States - statistics & facts","author":"Department SR","year":"2024"},{"key":"10.1016\/j.pcad.2024.12.010_bb0150","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1111\/ijcs.12961","article-title":"Young adults\u2019 online shopping addiction: the role of self-regulation and smartphone use","volume":"47","author":"Nyrhinen","year":"2023","journal-title":"Intl J Consumer Stud"},{"key":"10.1016\/j.pcad.2024.12.010_bb0155","doi-asserted-by":"crossref","first-page":"e594","DOI":"10.1016\/S2468-2667(24)00126-9","article-title":"The prevalence of gambling and problematic gambling: a systematic review and meta-analysis","volume":"9","author":"Tran","year":"2024","journal-title":"Lancet Public Health"},{"key":"10.1016\/j.pcad.2024.12.010_bb0160","first-page":"14","article-title":"Exploring the potential impact of GLP-1 receptor agonists on substance use, compulsive behavior, and libido: insights from social media using a mixed-methods approach","author":"Arillotta","year":"2024","journal-title":"Brain Sci"},{"key":"10.1016\/j.pcad.2024.12.010_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107312","article-title":"IUPHAR review - glucagon-like peptide-1 (GLP-1) and substance use disorders: an emerging pharmacotherapeutic target","volume":"207","author":"Bruns Vi","year":"2024","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.pcad.2024.12.010_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2024.112424","article-title":"Potential role of glucagon-like peptide-1 (GLP-1) receptor agonists in substance use disorder: a systematic review of randomized trials","volume":"264","author":"Martinelli","year":"2024","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.pcad.2024.12.010_bb0175","series-title":"Financial Times","article-title":"We may have passed peak obesity","author":"Burn-Murdoch","year":"2024"},{"key":"10.1016\/j.pcad.2024.12.010_bb0180","series-title":"GLP-1s like Ozempic Are among the most Important Drug Breakthroughs Ever - https:\/\/www.economist.com\/briefing\/2024\/10\/24\/glp-1s-like-ozempic-are-among-the-most-important-drug-breakthroughs-ever. Briefing","author":"Topol","year":"2024"},{"key":"10.1016\/j.pcad.2024.12.010_bb0185","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.tem.2020.02.006","article-title":"How may GIP enhance the therapeutic efficacy of GLP-1?","volume":"31","author":"Samms","year":"2020","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.pcad.2024.12.010_bb0190","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept","volume":"18","author":"Coskun","year":"2018","journal-title":"Mol Metab"},{"key":"10.1016\/j.pcad.2024.12.010_bb0195","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/ADM.0000000000001347","article-title":"The efficacy of GLP-1 agonists in treating substance use disorder in patients: a scoping review","volume":"18","author":"Shen","year":"2024","journal-title":"J Addict Med"},{"key":"10.1016\/j.pcad.2024.12.010_bb0200","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.774050","article-title":"An overview of appetite-regulatory peptides in addiction processes; from bench to bed side","volume":"15","author":"Shevchouk","year":"2021","journal-title":"Front Neurosci"},{"key":"10.1016\/j.pcad.2024.12.010_bb0205","doi-asserted-by":"crossref","first-page":"1092828","DOI":"10.3389\/fpsyt.2022.1092828","article-title":"Insight into the role of the gut-brain axis in alcohol-related responses: emphasis on GLP-1, amylin, and ghrelin","volume":"13","author":"Tufvesson-Alm","year":"2022","journal-title":"Front Psych"},{"key":"10.1016\/j.pcad.2024.12.010_bb0210","doi-asserted-by":"crossref","DOI":"10.1002\/clc.24314","article-title":"Glucagon-like Peptide-1 receptor agonists and major adverse cardiovascular events in patients with and without diabetes: a Meta-analysis of randomized-controlled trials","volume":"47","author":"Hosseinpour","year":"2024","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.pcad.2024.12.010_bb0215","first-page":"139","article-title":"Therapeutic advances in obesity: how real-world evidence impacts affordability beyond standard of care","volume":"15","author":"Patoulias","year":"2024","journal-title":"Pragmat Obs Res"},{"key":"10.1016\/j.pcad.2024.12.010_bb0220","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.pcad.2024.12.010_bb0225","doi-asserted-by":"crossref","DOI":"10.1177\/17562864241281903","article-title":"Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP\/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis","volume":"17","author":"Stefanou","year":"2024","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.pcad.2024.12.010_bb0230","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1016\/j.jacc.2024.08.007","article-title":"The effect of Semaglutide on mortality and COVID-19-related deaths: an analysis from the SELECT trial","volume":"84","author":"Scirica","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2024.12.010_bb0235","doi-asserted-by":"crossref","DOI":"10.3390\/nu16193238","article-title":"Tackling cravings in medical weight management: an update on pathophysiology and an integrated approach to treatment","volume":"16","author":"Kakoschke","year":"2024","journal-title":"Nutrients"},{"key":"10.1016\/j.pcad.2024.12.010_bb0240","doi-asserted-by":"crossref","DOI":"10.2337\/db23-128-OR","article-title":"The effect of Tirzepatide during weight loss on food intake, appetite, food preference, and food craving in people with obesity","volume":"72","author":"Martin","year":"2023","journal-title":"Diabetes"},{"key":"10.1016\/j.pcad.2024.12.010_bb0245","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/oby.23673","article-title":"Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight\/obesity: STEP 5","volume":"31","author":"Wharton","year":"2023","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.pcad.2024.12.010_bb0250","article-title":"Can GLP-1 be a target for reward system related disorders? A qualitative synthesis and systematic review analysis of studies on palatable food, drugs of abuse, and alcohol","volume":"14","author":"Eren-Yazicioglu","year":"2020","journal-title":"Front Behav Neurosci"},{"key":"10.1016\/j.pcad.2024.12.010_bb0255","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2024.12.010_bb0260","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1001\/jamainternmed.2024.2525","article-title":"Semaglutide vs Tirzepatide for weight loss in adults with overweight or obesity","volume":"184","author":"Rodriguez","year":"2024","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.pcad.2024.12.010_bb0265","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly Semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2024.12.010_bb0270","article-title":"Tirzepatide for obesity treatment and diabetes prevention","author":"Jastreboff","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2024.12.010_bb0275","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-hormone-receptor agonist Retatrutide for obesity - a phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2024.12.010_bb0280","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.27258","article-title":"Clinical outcomes of Tirzepatide or GLP-1 receptor agonists in individuals with type 2 diabetes","volume":"7","author":"Chuang","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.pcad.2024.12.010_bb0285","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2024.12.010_bb0290","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2024.12.010_bb0295","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2024.12.010_bb0300","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of Semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2024.12.010_bb0305","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/dom.15318","article-title":"Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT-1 post hoc analysis","volume":"26","author":"Hankosky","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.pcad.2024.12.010_bb0310","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/dom.14890","article-title":"Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses","volume":"25","author":"Kosiborod","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.pcad.2024.12.010_bb0315","article-title":"Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial","author":"Borlaug","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.pcad.2024.12.010_bb0320","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.pcad.2023.05.003","article-title":"Heart failure and obesity: the latest pandemic","volume":"78","author":"Aryee","year":"2023","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.pcad.2024.12.010_bb0325","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2024.12.010_bb0330","article-title":"Tirzepatide reduces LV mass and Paracardiac adipose tissue in obesity-related heart failure: SUMMIT CMR substudy","author":"Kramer","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2024.12.010_bb0335","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","author":"Packer","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2024.12.010_bb0340","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/dom.15410","article-title":"Effect of tirzepatide on albuminuria levels and renal function in patients with type 2 diabetes mellitus: a systematic review and multilevel meta-analysis","volume":"26","author":"Karakasis","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.pcad.2024.12.010_bb0345","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S2213-8587(22)00243-1","article-title":"Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial","volume":"10","author":"Heerspink","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.pcad.2024.12.010_bb0350","doi-asserted-by":"crossref","first-page":"4958","DOI":"10.1111\/dom.15898","article-title":"Beneficial effect of oral semaglutide for type 2 diabetes mellitus in patients with metabolic dysfunction-associated steatotic liver disease: a prospective, multicentre, observational study","volume":"26","author":"Arai","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.pcad.2024.12.010_bb0355","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous Semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2024.12.010_bb0360","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa2401755","article-title":"A phase 2 randomized trial of Survodutide in MASH and fibrosis","volume":"391","author":"Sanyal","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2024.12.010_bb0365","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1038\/s41591-024-03018-2","article-title":"Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial","volume":"30","author":"Sanyal","year":"2024","journal-title":"Nat Med"},{"issue":"13","key":"10.1016\/j.pcad.2024.12.010_bb0370","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","article-title":"Tirzepatide for the treatment of obstructive sleep apnea and obesity","volume":"391","author":"Malhotra","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2024.12.010_bb0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.113537","article-title":"Neuroprotective effects of GLP-1 receptor agonists in neurodegenerative disorders: a large-scale propensity-matched cohort study","volume":"143","author":"Siddeeque","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.pcad.2024.12.010_bb0380","doi-asserted-by":"crossref","first-page":"1033479","DOI":"10.3389\/fendo.2022.1033479","article-title":"The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer\u2019s disease","volume":"13","author":"Du","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.pcad.2024.12.010_bb0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106550","article-title":"Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: implications for neurodegenerative disease treatment","volume":"186","author":"Kopp","year":"2022","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.pcad.2024.12.010_bb0390","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1056\/NEJMoa2403664","article-title":"Once-weekly Semaglutide in persons with obesity and knee osteoarthritis","volume":"391","author":"Bliddal","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2024.12.010_bb0395","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1080\/14656566.2024.2391524","article-title":"The impact of approved anti-obesity medications on osteoarthritis","volume":"25","author":"Baser","year":"2024","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.pcad.2024.12.010_bb0400","article-title":"Clinical effects of glucagon-like Peptide-1 agonist use for weight loss in women with polycystic ovary syndrome: a scoping review","volume":"16","author":"Frangie Machado","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.pcad.2024.12.010_bb0405","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/alcalc\/agw040","article-title":"The prevalence of metabolic syndrome in alcohol use disorders: a systematic review and Meta-analysis","volume":"51","author":"Vancampfort","year":"2016","journal-title":"Alcohol Alcohol"},{"key":"10.1016\/j.pcad.2024.12.010_bb0410","doi-asserted-by":"crossref","first-page":"13027","DOI":"10.1038\/s41598-022-17190-3","article-title":"Differential association between the GLP1R gene variants and brain functional connectivity according to the severity of alcohol use","volume":"12","author":"Farokhnia","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.pcad.2024.12.010_bb0415","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.neuropharm.2018.01.013","article-title":"GLP-1 signaling and alcohol-mediated behaviors; preclinical and clinical evidence","volume":"136","author":"Jerlhag","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pcad.2024.12.010_bb0420","first-page":"8","article-title":"The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission","author":"Chuong","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.pcad.2024.12.010_bb0425","article-title":"Effect of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide on alcohol consumption in alcohol-preferring male vervet monkeys","author":"Fink-Jensen","year":"2024","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pcad.2024.12.010_bb0430","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s11064-023-04093-6","article-title":"Liraglutide reduces alcohol consumption, anxiety, memory impairment, and synapse loss in alcohol dependent mice","volume":"49","author":"Liu","year":"2024","journal-title":"Neurochem Res"},{"key":"10.1016\/j.pcad.2024.12.010_bb0435","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2020.599646","article-title":"Long-acting glucagon-like Peptide-1 receptor agonists suppress voluntary alcohol intake in male Wistar rats","volume":"14","author":"Marty","year":"2020","journal-title":"Front Neurosci"},{"key":"10.1016\/j.pcad.2024.12.010_bb0440","doi-asserted-by":"crossref","first-page":"20998","DOI":"10.1038\/s41598-023-48267-2","article-title":"Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity","volume":"13","author":"Quddos","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.pcad.2024.12.010_bb0445","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1007\/s13679-024-00577-w","article-title":"Alcohol misuse post metabolic and bariatric surgery: a systematic review of longer-term studies with focus on new onset alcohol use disorder and differences between surgery types","volume":"13","author":"Kenkre","year":"2024","journal-title":"Curr Obes Rep"},{"key":"10.1016\/j.pcad.2024.12.010_bb0450","series-title":"Q&A: Can Weight Loss Drugs Help in Addiction Treatment? - https:\/\/www.psu.edu\/news\/research\/story\/qa-can-weight-loss-drugs-help-addiction-treatment. Penn State News. Vol Research","author":"Yu","year":"2024"},{"key":"10.1016\/j.pcad.2024.12.010_bb0455","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.35247","article-title":"Semaglutide and opioid overdose risk in patients with type 2 diabetes and opioid use disorder","volume":"7","author":"Wang","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.pcad.2024.12.010_bb0460","article-title":"The association between glucose-dependent insulinotropic polypeptide and\/or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders: a real-world data analysis","author":"Qeadan","year":"2024","journal-title":"Addiction"},{"key":"10.1016\/j.pcad.2024.12.010_bb0465","doi-asserted-by":"crossref","DOI":"10.1016\/j.physbeh.2024.114565","article-title":"Targeting GLP-1 receptors to reduce nicotine use disorder: preclinical and clinical evidence","volume":"281","author":"Herman","year":"2024","journal-title":"Physiol Behav"},{"key":"10.1016\/j.pcad.2024.12.010_bb0470","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/nn.4540","article-title":"GLP-1 acts on habenular avoidance circuits to control nicotine intake","volume":"20","author":"Tuesta","year":"2017","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.pcad.2024.12.010_bb0475","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.7326\/M23-2718","article-title":"Association of Semaglutide with Tobacco use Disorder in patients with type 2 diabetes\u202f: target trial emulation using real-world data","volume":"177","author":"Wang","year":"2024","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.pcad.2024.12.010_bb0480","first-page":"5","article-title":"Social media as pharmacovigilance: the potential for patient reports to inform clinical research on glucagon-like peptide 1 (GLP-1) receptor agonists for substance use disorders","volume":"85","author":"Bremmer","year":"2024","journal-title":"J Stud Alcohol Drugs"},{"key":"10.1016\/j.pcad.2024.12.010_bb0485","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1038\/s41386-018-0010-3","article-title":"Glucagon-like peptide-1 receptor activation in the ventral tegmental area attenuates cocaine seeking in rats","volume":"43","author":"Hernandez","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pcad.2024.12.010_bb0490","author":"Ali"},{"key":"10.1016\/j.pcad.2024.12.010_bb0495","article-title":"Possible mechanisms underlying the effects of glucagon-like Peptide-1 receptor agonist on cocaine use disorder","volume":"13","author":"Zhu","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.pcad.2024.12.010_bb0500","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13841","article-title":"Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesity","volume":"26","author":"Mechanick","year":"2025","journal-title":"Obes Rev"},{"key":"10.1016\/j.pcad.2024.12.010_bb0505","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus Semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Frias","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2024.12.010_bb0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107401","article-title":"Glucagon-like peptide-1 receptor agonists and risk of gastrointestinal cancers: a systematic review and meta-analysis of randomized controlled trials","volume":"208","author":"Figlioli","year":"2024","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.pcad.2024.12.010_bb0515","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.21305","article-title":"Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes","volume":"7","author":"Wang","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.pcad.2024.12.010_bb0520","doi-asserted-by":"crossref","DOI":"10.2196\/65440","article-title":"Multifactor quality and safety analysis of Semaglutide products sold by online sellers without a prescription: market surveillance, content analysis, and product purchase evaluation study","volume":"26","author":"Ashraf","year":"2024","journal-title":"J Med Internet Res"}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062024001798?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062024001798?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T17:06:06Z","timestamp":1747847166000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033062024001798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":104,"alternative-id":["S0033062024001798"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2024.12.010","relation":{},"ISSN":["0033-0620"],"issn-type":[{"value":"0033-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-consumption agents: Tirzepatide and semaglutide for treating obesity-related diseases and addictions, and improving life expectancy","name":"articletitle","label":"Article Title"},{"value":"Progress in Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcad.2024.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}